Finanzas de Indaptus Therapeutics Inc (INDP)INDPIndaptus Therapeutics Inc

Evaluating the bottom line, Indaptus Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -318.04%, provide a clear picture of how effectively INDP converts its operational activities into shareholder value.

In the context of the broader market, INDP competes directly with industry leaders such as EIKN and SPRY. With a market capitalization of $421.05M, it holds a leading position in the sector. When comparing efficiency, INDP's gross margin of N/A stands against EIKN's N/A and SPRY's 61.83%. Such benchmarking helps identify whether Indaptus Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Indaptus has reported consistent net losses, with the latest quarterly net income showing a loss of $1,794,863. The company's current ratio is strong at 19.48, indicating good short-term financial health, but the overall profitability remains a concern due to negative earnings.